HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.

Abstract
EpCAM is a tumor-associated antigen, which is frequently expressed in ovarian cancer. Recently, autoantibodies against EpCAM have been identified in patients with ovarian cancer. It is not clear whether these autoantibodies are of prognostic importance. We evaluated whether EpCAM-autoantibodies have an impact on the clinical course of patients with ovarian cancer. EpCAM-autoantibodies were determined in sera of 28 healthy voluntary age-matched women and 84 patients with primary epithelial ovarian cancer before and after platinum-based chemotherapy using a recombinant EpCAM-protein for antibody detection by ELISA technique. The median follow-up time was 18 months. Samples exceeding the mean antibody titer of healthy controls plus 2 standard deviations were considered positive. The antibody titer of healthy controls was 0.061 ± 0.015. Using a cut-off value of 0.091, we found 3/84 (4%) patients before and 12/61 (20%) patients with ovarian cancer to be positive for EpCAM-autoantibodies after first-line treatment. Using the paired T-Test, we noted a significant post-therapeutic increase of AABs (P < 0.0001). Notably, AAB-levels after first-line therapy were found to be correlated with the tumor resection status in primary surgery. Analysis of progression-free survival, FIGO stage, grading, age and sensitivity to platinum-based chemotherapy did not reveal significant associations with EpCAM-AAB titers. We observed an increase in AAB-levels during the first-line treatment of patients with ovarian cancer. EpCAM-AAB-levels after first-line treatment appear to correlate with macroscopic tumor residuals after initial surgery.
AuthorsMartin Heubner, Dino Errico, Sabine Kasimir-Bauer, Dorothee Herlyn, Rainer Kimmig, Pauline Wimberger
JournalMedical oncology (Northwood, London, England) (Med Oncol) Vol. 28 Issue 2 Pg. 626-30 (Jun 2011) ISSN: 1559-131X [Electronic] United States
PMID20383668 (Publication Type: Journal Article)
Chemical References
  • Antigens, Neoplasm
  • Antineoplastic Agents
  • Autoantibodies
  • Autoantigens
  • Cell Adhesion Molecules
  • EPCAM protein, human
  • Epithelial Cell Adhesion Molecule
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antigens, Neoplasm (blood, immunology)
  • Antineoplastic Agents (therapeutic use)
  • Autoantibodies (blood, immunology)
  • Autoantigens (immunology)
  • Cell Adhesion Molecules (blood, immunology)
  • Enzyme-Linked Immunosorbent Assay
  • Epithelial Cell Adhesion Molecule
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Neoplasms, Glandular and Epithelial (drug therapy, immunology, pathology)
  • Ovarian Neoplasms (drug therapy, immunology, pathology)
  • Prognosis
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: